Dupilumab Data at EADV 2026 Highlight Outcomes Across AD, CSU, and Prurigo Nodularis

New data presented at the 2026 European Academy of Dermatology and Venereology (EADV) Congress highlight the effects of dupilumab (Dupixent) across atopic dermatitis (AD), chronic spontaneous urticaria (CSU), and prurigo nodularis (PN), with findings spanning clinical disease control, itch, growth, and quality of life.

A total of 33 abstracts featuring dupilumab are being presented at EADV 2026. Among the findings are analyses of pediatric growth in AD, real-world outcomes among adolescents with AD, quality-of-life improvements in patients with CSU, and real-world effectiveness in adults with PN.

Pediatric AD Data Explore Growth and Weight Outcomes

An analysis of pivotal clinical trials evaluated the impact of dupilumab on weight and body mass index (BMI) among children with moderate to severe AD.

Children who were in lower weight percentiles at baseline experienced greater gains in weight with dupilumab compared with placebo, supporting a trend toward age-expected growth trajectories. Similar trends were observed for improvements in BMI.

The findings highlight the potential broader effects of controlling moderate to severe AD in pediatric patients, particularly among children who are underweight.

Real-World Findings Show Sustained Benefits for Adolescents With AD

Two analyses from the real-world RELIEVE-AD-PEDs study evaluated outcomes among adolescents with moderate to severe AD receiving dupilumab in clinical practice.

One analysis focused on patient and caregiver quality of life and productivity. After 1 year of treatment, adolescents and their caregivers reported improvements in health-related quality of life, sleep, and work or school outcomes.

A separate analysis examined disease control over the same period. Improvements in disease control were observed as early as 2 weeks after dupilumab initiation and were sustained through 1 year. At 1 year, the majority of adolescents also reported improvements in disease severity, itch, and treatment satisfaction.

Together, the findings provide additional real-world evidence regarding the impact of treatment on both clinical and day-to-day outcomes among adolescents living with moderate to severe AD.

Dupilumab Improves Quality-of-Life Measures in CSU

Additional data presented at EADV evaluated disease-specific quality of life among omalizumab-naïve adults and adolescents with CSU.

The post hoc pooled analysis included patients from the phase 3 LIBERTY-CSU CUPID Study A and Study C trials. Dupilumab significantly improved health-related quality of life, with improvements observed across domains related to appearance, sleep, daily limitations, and itch.

The findings add to evidence examining the effects of CSU treatment beyond clinical disease measures, including the broader burden that persistent itch and other symptoms can have on patients' daily lives.

Real-World PN Data Demonstrate Improvements in Itch and Disease Severity

Real-world findings presented at EADV also examined dupilumab treatment among adults with PN.

Three-month findings from GLOBOSPIN, a global observational study, showed reductions in both the overall number of lesions and the number of itchy lesions among adults with PN receiving dupilumab.

A separate systematic literature review and meta-analysis assessed the real-world effectiveness of dupilumab in adults with moderate to severe PN. Across the included evidence, dupilumab was associated with substantial and sustained improvements in itch and disease severity, supporting findings observed with its use in routine clinical practice.

Collectively, the EADV 2026 presentations expand the available evidence surrounding dupilumab across multiple type 2 inflammatory skin diseases, including outcomes that extend beyond traditional measures of disease severity to encompass itch, quality of life, productivity, and pediatric growth.

References

1. Sanofi and Regeneron. Dupixent (dupilumab) data to be presented at the European Academy of Dermatology and Venereology Congress 2026. Embargoed materials provided to Dermatology Times. September 2026.
2. Casale TB, Saini SS, Ben-Shoshan M, et al. Dupilumab in patients with chronic spontaneous urticaria: Phase 3 LIBERTY-CSU CUPID randomized clinical trials. JAMA Dermatol. 2026;162(4):350-358. doi:10.1001/jamadermatol.2025.6023
3. Casale TB, Saini SS, Bernstein JA, et al. Dupilumab improves health-related quality of life in omalizumab-naïve patients with chronic spontaneous urticaria. Dermatol Ther (Heidelb). 2026. doi:10.1007/s13555-025-01605-w
4. Maurer M, Casale TB, Saini SS, et al. Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials. J Allergy Clin Immunol. 2024. doi:10.1016/j.jaci.2024.01.027